Amgen (AMGN) Retained Earnings (2009 - 2026)
Amgen (AMGN) recorded quarterly Retained Earnings of -$190.0 million in Q1 2026, up 26.36% quarter-over-quarter from -$258.0 million in Q4 2025, and up 99.3% on a YoY basis from -$95.3 million in Q1 2025.
Amgen (AMGN) Retained Earnings (2009 - 2026) Analysis & Trends
Amgen's Retained Earnings history runs 18 years deep, the most recent figure standing at -$190.0 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.3% year-over-year to -$190.0 million; the TTM figure through Mar 2026 stood at -$190.0 million (up 99.3% YoY), while the FY2025 annual figure was -$258.0 million, up 99.06% from the prior year.
- Retained Earnings was -$190.0 million for Q1 2026 at Amgen, up from -$258.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$126.0 million in Q3 2023 to a low of -$29.6 billion in Q1 2022.
- Historically, Retained Earnings has averaged -$9.8 billion across 5 years, with a median of -$544.0 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings plunged 20161.9% in 2024, then jumped 99.3% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$231.0 million in 2022, then fell by 25.11% to -$289.0 million in 2023, then plunged by 9446.71% to -$27.6 billion in 2024, then jumped by 99.06% to -$258.0 million in 2025, then climbed by 26.36% to -$190.0 million in 2026.
- The last three Retained Earnings figures came in at -$190.0 million (Q1 2026), -$258.0 million (Q4 2025), and -$422.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190.00 Mn |
| Dec 31, 2025 | -258.00 Mn |
| Sep 30, 2025 | -422.00 Mn |
| Jun 30, 2025 | -544.00 Mn |
| Mar 31, 2025 | -27.14 Bn |
| Dec 31, 2024 | -27.59 Bn |
| Sep 30, 2024 | -25.53 Bn |
| Jun 30, 2024 | -27.12 Bn |
| Mar 31, 2024 | -190.00 Mn |
| Dec 31, 2023 | -289.00 Mn |
| Sep 30, 2023 | -126.00 Mn |
| Jun 30, 2023 | -25.54 Bn |
| Mar 31, 2023 | -268.00 Mn |
| Dec 31, 2022 | -231.00 Mn |
| Sep 30, 2022 | -652.00 Mn |
| Jun 30, 2022 | -672.00 Mn |
| Mar 31, 2022 | -29.57 Bn |
| Dec 31, 2021 | -796.00 Mn |
| Sep 30, 2021 | -808.00 Mn |
| Jun 30, 2021 | -22.76 Bn |